NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









uBriGene Biosciences

uBriGene Biosciences

Private
Germantown, MarylandHealthcare & Life Scienceshttps://www.ubrigene.com/

Last Round

VC Round

Dec 24, 2024

Total Funding Raised

$66M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

uBriGene Biosciences is a biotechnology company that provides contract development and manufacturing organization (CDMO) services for the cell and gene therapy industry.

Sector

Healthcare & Life Sciences

Verticals

Pharma Supply Chain, Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

CDMOContract Development and Manufacturing Organizationcell therapy manufacturinggene therapy manufacturingCGT CDMOviral vector manufacturingGMP manufacturingadvanced therapy medicinal productsATMPpharma outsourcingplasmid DNA manufacturingAAV manufacturinglentivirus manufacturingCAR-T manufacturingmRNA manufacturingiPSC banksCRO

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

uBriGene Biosciences Comparables

Compare uBriGene Biosciences with similar companies based on industry and business-model similarity.

uBriGene Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Zhejiang Innoforce Pharmaceuticals
90%
CoJourney
85%
Beijing Fiveplus Gene Technology
84%

uBriGene Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundDec 24, 2024
Series C ExtensionApr 19, 2023
Series CSep 27, 2022
Series BSep 16, 2021
Series ADec 16, 2020
Angel
Oct 1, 2019

uBriGene Biosciences Investors

Notable investors and investment history

uBriGene Biosciences investors
InvestorRounds
BGI Co-WinSeries C
IDG CapitalSeries C, Series B
中信金石投资有限公司Series C
Innovator CapitalSeries C
Wenzhou State-owned Financial Capital ManagementSeries C
Beijing Fangfu Venture Capital ManagementSeries C Extension, Series C, Series A, Series B
Huagai CapitalSeries C, Series B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 11, representing 48% of headcount.

  • Jul 13, 2026

    Open roles increased from 0 to 5, representing 22% of headcount.

uBriGene Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

uBriGene Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about uBriGene Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersGermantown, Maryland
Employee Range23
Year Founded2015
Last FundingDec 24, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.